Early Treatment Response to Intravitreal Aflibercept 8mg in Patients With Exudative Age-Related Macular Degeneration

What this Trial Is About

This research aims to evaluate early treatment responses in patients aged 50 and older with exudative age-related macular degeneration AMD. It focuses on observing retinal fluid changes and visual acuity improvements after treatment with intravitreal aflibercept 8 mg, an anti-VEGF drug, during the initial two months. The study also explores how early treatment outcomes may help predict future treatment needs over a year. Participants receive intravitreal injections of aflibercept 8 mg and undergo weekly check-ups from the first injection until the second, followed by a final visit and a third injection. These visits include retinal imaging using optical coherence tomography OCT to assess fluid levels in various retinal layers and monitoring of disease activity. The study is observational and open-label, meaning all participants receive the treatment and are monitored closely without a placebo group. During the two-month study period, researchers measure changes in retinal fluid, detection of specific retinal features, and best-corrected visual acuity using ETDRS charts. Patients are followed from initial treatment through weekly assessments to evaluate anatomical and functional responses. Data on treatment demand up to 12 months are also collected without additional study visits. The study aims to provide detailed insight into early treatment effects and their potential to guide longer-term therapy.

EarLy Treatment Response in nEoVascular Macular Degeneration With Eylea 8mg: ELEV8 A Prospective Observational Open Label Study Investigating the Fluid Dynamics During Early Response to Aflibercept 8mg in Patients With Exudative Age-related Macular Degeneration (AMD).